‘This Is Not the End of the Story’: What We Heard This Week

“This is not the end of the story for the inflammatory hypothesis in mood disorders.” — Muhammad Ishrat Husain, MD, of the Centre for Addiction and Mental Health in Toronto on NSAIDs’ failure to improve bipolar depression in a randomized trial.

“It’s not a panacea and it’s not a cure-all.” — David Aronoff, MD, of Vanderbilt University Medical Center in Nashville, commenting on the results of the remdesivir trial in COVID-19 patients, and whether the medication can be used to treat COVID-19 patients outside of a clinical trial setting.

“We are here to protect the integrity of the medical profession. To make sure doctors who are practicing legitimately can do so with these drugs, but also that opioid addicts aren’t used for schemes that profit from and grow their suffering.” — Assistant U.S. Attorney Ben Barron, speaking on the severity of the sentence in an opioid kickback scheme.

“The finding is exciting as it takes us beyond just focusing on age and comorbidities as risk factors for severe COVID-19.” — David Melzer, MBBCh, PhD, of the University of Exeter in England, discussing a possible link between the coronavirus and Alzheimer’s risk gene APOE4.

“We don’t know because we are not being tested. We are told to come to work unless symptomatic.” — an anonymous physician’s response in the MedPage Today COVID-19 benchmarking survey when asked how many clinicians are not at work, because they’re sick or hospitalized.

“More desperately needed clinical trials may be stopped as a result of this study.” — Matthew Spinelli, MD, of the University of California San Francisco, on inconsistencies in a large trial showing increased risk from hydroxychloroquine treatment in hospitalized COVID-19 patients.

Last Updated May 29, 2020